Compound
Casanat® 40 mg
Active ingredient: cabozantinib (S)-malate in terms of cabozantinib 40 mg-50.69 mg
Excipients: microcrystalline cellulose PH-102 62.16 mg, anhydrous lactose 31.07 mg, hyprolose (hydroxypropylcellulose) 4.800 mg, croscarmellose sodium 9.600 mg, colloidal silicon dioxide (anhydrous) 0.4800 mg, magnesium stearate 1.200 mg.
Indications for use
The drug Kasanat® is intended for the treatment of advanced renal cell carcinoma:
• in adult patients with an intermediate or poor prognosis who have not previously received therapy;
• in adult patients after previous therapy with antiangiogenic drugs (VEGF-targeted therapy).
Contraindications
Hypersensitivity to the active substance or to any of the components of the drug, severe renal and liver failure, pregnancy and breastfeeding, children under 18 years of age.
Carefully
For inflammatory bowel disease (eg Crohn’s disease, ulcerative colitis, peritonitis, diverticulitis or appendicitis); tumor infiltration into the gastrointestinal tract; a complication from a previous surgical operation (especially when it is associated with slow or incomplete wound healing); history of arterial thromboembolism (or in patients at risk for such a condition); history of venous thromboembolism (including pulmonary embolism) (or in patients at risk for such a condition); arterial hypertension; when taking drugs that are potent inhibitors of CYP3A4; when taking drugs that are P-glycoprotein substrates; with simultaneous use of MRP2 inhibitors; in patients with a history of QT interval prolongation; in patients taking antiarrhythmic drugs; in patients with existing heart disease, bradycardia or fluid and electrolyte imbalance; in patients with mild or moderate renal failure; in patients with mild or moderate liver failure; galactose intolerance, lactase deficiency or glucose-galactose malabsorption.
Should not be used in patients who are at risk or have a history of severe bleeding.
Chronic use of concomitant medications that are strong CYP3A4 inducers should be avoided.
Use during pregnancy and breastfeeding
Women of reproductive age/Contraception in men and women
Women of reproductive potential should avoid pregnancy during treatment with cabozantinib. Female partners of men receiving cabozantinib should also avoid pregnancy. Effective methods of contraception should be used by male and female patients and their partners during therapy and for at least 4 months after completion of therapy. Because oral contraceptives cannot be considered an «effective method of contraception», they should be used in conjunction with another method, such as a barrier method.
Pregnancy
Cabozantinib has not been studied in pregnant women. Animal studies have shown embryofetal and teratogenic effects. The potential risk to humans is unknown.
Breast-feeding
It is unknown whether cabozantinib and/or its metabolites are excreted in breast milk. Due to the potential harm to the baby, breastfeeding should be discontinued during treatment with cabozantinib and for at least 4 months after completion of therapy.
Fertility
There are no data on the effect on fertility. Based on preclinical safety data, fertility in both men and women may be impaired during treatment with cabozantinib. Both men and women should consult with a specialist to discuss fertility preservation before initiating treatment with cabozantinib.
Directions for use and doses
Therapy with Casanat® should be carried out by a physician experienced in the use of anticancer drugs.
Dosage regimen
Inside.
The tablets should be swallowed whole and not broken. You should refrain from eating at least 2 hours before and 1 hour after taking Casanat®.
The recommended dose of Kasanat® is 60 mg once a day. Treatment should be continued as long as there is clinical benefit from therapy or until unacceptable toxicity develops.
If adverse reactions develop, it may be necessary to temporarily discontinue therapy and/or reduce the dose of Kasanat®. When dose reduction is required, it is recommended to reduce first to 40 mg daily and then to 20 mg daily. Temporary cessation of therapy is recommended for the development of grade 3 or greater adverse reactions or grade 2 intolerable toxicity. Dose reduction is recommended when adverse reactions are persistent, may become severe, or become intolerable.
If the patient misses a dose, the missed dose should not be taken unless the next dose is less than the next one e 12 o’clock.
Where to buy Cazanat Cabozantinib 40mg?
The most convenient option is to purchase the medicine from an online pharmacy. The main thing is to give preference to a certified pharmacy that complies with all drug storage standards. In the online pharmacy PHARMA LAB, all oncological drugs are stored in accordance with European standards and are purchased exclusively from official manufacturers.
Отзывы
Отзывов пока нет.